{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["36(10)"],"submitter":["Kubasch AS"],"funding":["Amgen"],"pubmed_abstract":["The EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and thrombocytopenia within the 'European Myelodysplastic Neoplasms Cooperative Group' (EMSCO) network. A total of 77 patients with LR-MDS and a median platelet count of 25/nl were included, all patients received ROM at a starting dose of 750 μg by SC injection weekly. Thirty-two patients (42%) achieved a hematologic improvement of platelets (HI-P) with a median duration of 340 days. Neutrophil (HI-N) and erythroid (HI-E) responses were observed in three (4%) and seven (9%) patients, respectively. We could not confirm previous reports that HI-P correlated with baseline endogenous thrombop"],"journal":["Leukemia"],"pagination":["2519-2527"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9522582"],"repository":["biostudies-literature"],"pubmed_title":["Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO."],"pmcid":["PMC9522582"],"pubmed_authors":["Thiede C","Huetter-Kroenke ML","Slama B","Ades L","Giagounidis A","Gotze KS","Fenaux P","De Renzis B","Cony-Makhoul P","Metzeler KH","Mies A","Sapena R","Kubasch AS","Schlenk RF","Jersemann K","Gloaguen S","Gourin MP","Metzgeroth G","Platzbecker U","Diaz JMT","Dimicoli-Salazar S","Schipp D","Herbst R","Laribi K","Park S","Sockel K","Jonasova A","Tiebel O","Chermat F"],"additional_accession":[]},"is_claimable":false,"name":"Prospective validation of a biomarker-driven response prediction model to romiplostim in lower-risk myelodysplastic neoplasms - results of the EUROPE trial by EMSCO.","description":"The EUROPE phase 2 trial investigated the predictive value of biomarkers on the clinical efficacy of single agent romiplostim (ROM) treatment in patients with lower-risk myelodysplastic neoplasms (LR-MDS) and thrombocytopenia within the 'European Myelodysplastic Neoplasms Cooperative Group' (EMSCO) network. A total of 77 patients with LR-MDS and a median platelet count of 25/nl were included, all patients received ROM at a starting dose of 750 μg by SC injection weekly. Thirty-two patients (42%) achieved a hematologic improvement of platelets (HI-P) with a median duration of 340 days. Neutrophil (HI-N) and erythroid (HI-E) responses were observed in three (4%) and seven (9%) patients, respectively. We could not confirm previous reports that HI-P correlated with baseline endogenous thrombop","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Oct","modification":"2026-05-31T15:57:12.162Z","creation":"2024-12-04T01:58:26.498Z"},"accession":"S-EPMC9522582","cross_references":{"pubmed":["36071100"],"doi":["10.1038/s41375-022-01669-z"]}}